Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Liminatus Pharma Inc. (LIMN : NSDQ)

• Company Description    Liminatus Pharma LLC operates as a clinical-stage immuno-oncology company which develops novel cancer therapies. Liminatus Pharma LLC is based in LA Palma, California. Number of Employees: 1

• Price / Volume Information    Yesterday's Closing Price: $3.47 Daily Weekly Monthly 20 Day Moving Average: 62,869 shares Shares Outstanding: 1.34 (millions) Market Capitalization: $4.66 (millions) Beta: 5.30 52 Week High: $141.50 52 Week Low: $3.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -53.70% -52.84% 12 Week -41.78% -42.97% Year To Date -88.62% -89.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2251 Stern Goodman Street Suite E - Fullerton,CA 92833 USA ph: 213-273-5453 fax: - None https://liminatuspharma.com

• General Corporate Information    Officers Chris Kim - Chief Executive Officer Scott Dam - Chief Financial Officer Eun Sook Lee - Director Nicholas Fernandez - Director Ji Yeon Baek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 53271X207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 1.34 Most Recent Split Date: 8.00 (0.02:1) Beta: 5.30 Market Capitalization: $4.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - -256.58 03/31/26 - -299.79 12/31/25 - -437.41 Current Ratio 06/30/26 - 1.12 03/31/26 - 0.96 12/31/25 - 0.05 Quick Ratio 06/30/26 - 1.12 03/31/26 - 0.96 12/31/25 - 0.05 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 0.27 03/31/26 - -0.15 12/31/25 - -18.13 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - 0.00 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©